A Placebo-Controlled Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacokinetics of MK-8245 in Subjects With Type 2 Diabetes
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2017
At a glance
- Drugs MK 8245 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 30 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jan 2010 Planned end date changed from 1 Nov 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.
- 30 Oct 2009 Actual initiation date changed from 1 Oct 2009 to 1 Sep 2009 as reported by ClinicalTrials.gov.